PDF(Pubmed)
Abstract：
UNASSIGNED: Studies have shown that sphingomyelin (SM) and its metabolites play signaling roles in the regulation of human health. Endogenous SM is involved in metabolic syndrome (MetS), while dietary SM supplementation may maintain lipid metabolism and prevent or alleviate MetS. Therefore, we hypothesized that dietary SM supplementation is beneficial for human health.
UNASSIGNED: In order to examine the impacts of dietary SM on metabolic indexes in adults without MetS, we performed a meta-analysis to test our hypothesis.
UNASSIGNED: A comprehensive search was performed to retrieve randomized controlled trials that were conducted between 2003 and 2023 to examine the effects of dietary SM supplementation on metabolic parameters in the Cochrane Library, PubMed, Web of Science, Embase, and ClinicalTrials.gov databases. RevMan 5.4 and Stata 14.0 software were used for meta-analysis, a sensitivity analysis, the risk of bias, and the overall quality of the resulted evidence.
UNASSIGNED: Eventually, 10 articles were included in this meta-analysis. Dietary SM supplementation did not affect the endline blood SM level. When compared to the control, SM supplementation reduced the blood total cholesterol level [MD: -12.97, 95% CI: (-14.57, -11.38), p < 0.00001], low-density lipoprotein cholesterol level [MD: -6.62, 95% CI: (-10.74, -2.49), p = 0.002], and diastolic blood pressure [MD: -3.31; 95% CI (-4.03, -2.58), p < 0.00001] in adults without MetS. The supplementation also increased high-density lipoprotein level [MD:1.41, 95% CI: (0.94, 1.88), p < 0.00001] and muscle fiber conduction velocity [MD: 95% 1.21 CI (0.53, 1.88), p = 0.0005]. The intake of SM had no effect on the blood phospholipids and lyso-phosphatidylcholine, but slightly decreased phosphatidylcholine, phosphatidylethanolamine, and phosphatidylinositol concentrations. Dietary SM supplementation reduced insulin level [MD: -0.63; 95% CI (-0.96, -0.31), p = 0.0001] and HOMA-IR [MD: -0.23; 95% CI (-0.31, -0.16), p < 0.00001] without affecting blood levels of glucose and inflammatory cytokines.
UNASSIGNED: Overall, dietary SM supplementation had a protective effect on blood lipid profiles and insulin level, but had limited impacts on other metabolic parameters in adults without MetS. More clinical trials and basic research are required.
UNASSIGNED: PROSPERO, identifier CRD42023438460.
UNASSIGNED: In order to examine the impacts of dietary SM on metabolic indexes in adults without MetS, we performed a meta-analysis to test our hypothesis.
UNASSIGNED: A comprehensive search was performed to retrieve randomized controlled trials that were conducted between 2003 and 2023 to examine the effects of dietary SM supplementation on metabolic parameters in the Cochrane Library, PubMed, Web of Science, Embase, and ClinicalTrials.gov databases. RevMan 5.4 and Stata 14.0 software were used for meta-analysis, a sensitivity analysis, the risk of bias, and the overall quality of the resulted evidence.
UNASSIGNED: Eventually, 10 articles were included in this meta-analysis. Dietary SM supplementation did not affect the endline blood SM level. When compared to the control, SM supplementation reduced the blood total cholesterol level [MD: -12.97, 95% CI: (-14.57, -11.38), p < 0.00001], low-density lipoprotein cholesterol level [MD: -6.62, 95% CI: (-10.74, -2.49), p = 0.002], and diastolic blood pressure [MD: -3.31; 95% CI (-4.03, -2.58), p < 0.00001] in adults without MetS. The supplementation also increased high-density lipoprotein level [MD:1.41, 95% CI: (0.94, 1.88), p < 0.00001] and muscle fiber conduction velocity [MD: 95% 1.21 CI (0.53, 1.88), p = 0.0005]. The intake of SM had no effect on the blood phospholipids and lyso-phosphatidylcholine, but slightly decreased phosphatidylcholine, phosphatidylethanolamine, and phosphatidylinositol concentrations. Dietary SM supplementation reduced insulin level [MD: -0.63; 95% CI (-0.96, -0.31), p = 0.0001] and HOMA-IR [MD: -0.23; 95% CI (-0.31, -0.16), p < 0.00001] without affecting blood levels of glucose and inflammatory cytokines.
UNASSIGNED: Overall, dietary SM supplementation had a protective effect on blood lipid profiles and insulin level, but had limited impacts on other metabolic parameters in adults without MetS. More clinical trials and basic research are required.
UNASSIGNED: PROSPERO, identifier CRD42023438460.
摘要：
■研究表明，鞘磷脂（SM）及其代谢产物在调节人类健康中起信号作用。内源性SM与代谢综合征（MetS）有关，而膳食补充SM可以维持脂质代谢并预防或缓解MetS。因此,我们假设膳食补充SM对人类健康有益。
■为了研究饮食SM对没有MetS的成年人的代谢指标的影响，我们进行了荟萃分析以检验我们的假设.
■进行了全面搜索，以检索在2003年至2023年之间进行的随机对照试验，以检查饮食补充SM对Cochrane文库中代谢参数的影响，PubMed,WebofScience,Embase,和ClinicalTrials.gov数据库。采用RevMan5.4和Stata14.0软件进行荟萃分析，敏感性分析，偏见的风险，以及结果证据的总体质量。
■最终，本荟萃分析包括10篇文章。饮食补充SM不会影响端线血液SM水平。与对照相比，补充SM降低了血液总胆固醇水平[MD：-12.97，95％CI：（-14.57，-11.38），p<0.00001],低密度脂蛋白胆固醇水平[MD：-6.62，95%CI：（-10.74，-2.49），p=0.002],和舒张压[MD：-3.31；95%CI（-4.03，-2.58），p<0.00001]在没有MetS的成年人中。补充也增加了高密度脂蛋白水平[MD：1.41，95％CI：（0.94，1.88），p<0.00001]和肌纤维传导速度[MD：95%1.21CI（0.53，1.88），p=0.0005]。SM的摄入对血液磷脂和溶血磷脂酰胆碱没有影响，但磷脂酰胆碱略有减少，磷脂酰乙醇胺，和磷脂酰肌醇浓度。膳食补充SM可降低胰岛素水平[MD：-0.63;95％CI（-0.96，-0.31），p=0.0001]和HOMA-IR[MD：-0.23；95%CI（-0.31，-0.16），p<0.00001]不影响血糖和炎性细胞因子的血液水平。
■总的来说，膳食补充SM对血脂和胰岛素水平有保护作用，但对没有MetS的成年人的其他代谢参数影响有限。需要更多的临床试验和基础研究。
■PROSPERO，标识符CRD42023438460。
■为了研究饮食SM对没有MetS的成年人的代谢指标的影响，我们进行了荟萃分析以检验我们的假设.
■进行了全面搜索，以检索在2003年至2023年之间进行的随机对照试验，以检查饮食补充SM对Cochrane文库中代谢参数的影响，PubMed,WebofScience,Embase,和ClinicalTrials.gov数据库。采用RevMan5.4和Stata14.0软件进行荟萃分析，敏感性分析，偏见的风险，以及结果证据的总体质量。
■最终，本荟萃分析包括10篇文章。饮食补充SM不会影响端线血液SM水平。与对照相比，补充SM降低了血液总胆固醇水平[MD：-12.97，95％CI：（-14.57，-11.38），p<0.00001],低密度脂蛋白胆固醇水平[MD：-6.62，95%CI：（-10.74，-2.49），p=0.002],和舒张压[MD：-3.31；95%CI（-4.03，-2.58），p<0.00001]在没有MetS的成年人中。补充也增加了高密度脂蛋白水平[MD：1.41，95％CI：（0.94，1.88），p<0.00001]和肌纤维传导速度[MD：95%1.21CI（0.53，1.88），p=0.0005]。SM的摄入对血液磷脂和溶血磷脂酰胆碱没有影响，但磷脂酰胆碱略有减少，磷脂酰乙醇胺，和磷脂酰肌醇浓度。膳食补充SM可降低胰岛素水平[MD：-0.63;95％CI（-0.96，-0.31），p=0.0001]和HOMA-IR[MD：-0.23；95%CI（-0.31，-0.16），p<0.00001]不影响血糖和炎性细胞因子的血液水平。
■总的来说，膳食补充SM对血脂和胰岛素水平有保护作用，但对没有MetS的成年人的其他代谢参数影响有限。需要更多的临床试验和基础研究。
■PROSPERO，标识符CRD42023438460。
